LEXICON PHARMACEUTICALS, INC.
LXRX · XNASCIK 1062822fmd_1FQ13XJ4TN2SEES4QBJYXJM5CCManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 79 | 92 | 63 | 322 | 24 | 0 | 0 | 1 | 31 | 50 |
| Cost of revenue | 0 | 2 | 2 | 3 | 2 | 0 | 0 | 0 | 1 | 0 |
| Realized investment gains (losses) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 79 | 90 | 61 | 319 | 22 | 0 | 0 | 1 | 30 | 50 |
| Research and development | 164 | 152 | 100 | 92 | 154 | 55 | 53 | 59 | 84 | 61 |
| Selling, general and administrative | – | – | – | – | – | 32 | 48 | 114 | 143 | 37 |
| Total operating expenses | 206 | 222 | 166 | 181 | 204 | 87 | 101 | – | – | – |
| Impairment of real estate | – | – | 0 | 0 | 2 | 0 | 0 | – | – | – |
| Operating income | (127) | (131) | (103) | 141 | (48) | (87) | (101) | (172) | (197) | (49) |
| Interest expense | 7 | 7 | 21 | 21 | 15 | 1 | 3 | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 2 | 2 | 4 | 3 | 3 | 0 | 2 | 8 | 12 | 7 |
| Income before taxes | (131) | (136) | (121) | 124 | (59) | (88) | – | – | – | – |
| Income tax expense | 0 | – | – | – | – | 0 | 0 | 0 | 0 | – |
| Net income from continuing operations | (131) | – | – | – | – | (88) | – | – | – | – |
| Net income | (131) | (123) | (121) | 130 | (59) | (88) | (102) | (177) | (200) | (50) |